Pharmaceutical Companies
Extend discovery capacity without adding headcount
Computational depth with the experimental evidence attached, delivered under one agreement - with the documentation and quality standards your qualification process expects.
What we hear
What we hear from discovery and translational leaders
- More programmes than internal computational capacity, and hiring is not the fastest route
- Vendor sprawl: a software supplier, a laboratory supplier and a hand-off between them that nobody owns
- Pressure to demonstrate AI adoption with evidence that survives audit
- Late-stage attrition on properties that were predictable early
What we do about it
One workstream, one accountable lead
We take a defined programme - a target, a series, a biomarker - and run computation and bench work as one workstream with one accountable lead. You get an evidence package, not a slide deck, and the methodology record that lets your own scientists interrogate every conclusion.
Where we typically start
Entry points that pay for themselves first
| Entry point | Why |
|---|---|
| Lead Optimisation & ADMET | Immediate, measurable effect on attrition risk |
| Biomarker Discovery & Validation | Translational medicine teams have budget and urgency |
| Dedicated Teams | Reserved capacity without permanent headcount |
| Molecular Diagnostics Development | Protects the label and the Phase III timeline |
How engagements run
Programme budgets typically run USD 250K–2M. Expect vendor qualification, security review and a master service agreement - we have been through it before and will send the capability and quality overview ahead of the first meeting, not after the fourth.
On data and IP
Your data and results are yours. Our models, pipelines and platform remain ours. Co-developed IP is negotiated explicitly before work starts, never after. We raise this in the first meeting because it is the issue that most often derails good technical relationships late.
Enterprise AI for Life Sciences
Ready to Advance Your Drug Discovery Pipeline?
Partner with Prognica Labs to leverage enterprise-grade AI, computational chemistry, and molecular simulation technologies that accelerate discovery, reduce development risk, and improve R&D productivity.
From biotech startups to global pharmaceutical organizations, we help research teams make faster, evidence-driven decisions across every stage of early drug discovery.